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Guido Heine3, Gerd R Burmester1, Simon Fillatreau2 and Thomas Dörner1,2*Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a break in self-tolerance
reflected by a production of antinuclear autoantibodies. Since autoantibody production can be activated via nucleic
acid Toll-like receptor 9 (TLR9), the respective pathway has been implicated in the development of SLE and pathogenic
B cell responses. However, the response of B cells from SLE patients to TLR9 stimulation remains incompletely
characterized.
Methods: In the current study, the response of B cells from SLE patients and healthy donors upon TLR9 stimulation
was analyzed in terms of proliferation and cytokine production and correlated with the lupus disease activity and
anti-dsDNA titers.
Results: B cells from SLE patients showed a reduced response to TLR9 agonist compared to B cells from healthy
donors in terms of proliferation and activation. B cells from SLE patients with higher disease activity produced less
interleukin (IL)-6, IL-10, vascular endothelial growth factor, and IL-1ra than B cells from healthy donors. Further analyses
revealed an inverse correlation of cytokines produced by TLR9-stimulated B cells with lupus disease activity and
anti-dsDNA titer, respectively.
Conclusion: The capacity of B cells from lupus patients to produce cytokines upon TLR9 engagement becomes less
efficient with increasing disease activity, suggesting that they either enter an exhausted state or become tolerant to
TLR stimulation for cytokine production when disease worsens.Introduction
Systemic lupus erythematosus (SLE) is a severe systemic
autoimmune disease with heterogeneous clinical mani-
festations [1]. A hallmark of SLE immunopathology is
B-cell hyperactivity leading to increased numbers of circu-
lating plasma cells [2] and a breakdown of self-tolerance
toward DNA and nucleoproteins, which is reflected by
elevated levels of antinuclear autoantibodies, such as anti-
double-stranded (ds)DNA, anti-ribonucleoprotein and
other autoantibodies [3]. In addition, SLE is associated* Correspondence: thomas.doerner@charite.de
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stated.with abnormal cytokine levels, including increased levels
of type I interferon (IFN), IL-6, TNF-α, and B-cell acti-
vating factor (BAFF), which are thought to have funda-
mental roles in the maintenance and progression of this
inflammatory disease [4-12].
The role of B cells in immunity has been mainly re-
lated to the generation of antibodies and formation of
immune complexes for a long period of time. However,
B cells can exert additional functions, such as antigen
presentation, activation of T cells, formation of lymphoid
organs and secretion of cytokines, but their contribution
in human autoimmunity has not been comprehensively
explored [13-16]. However, there is now clear evidence
that cytokine-producing B cells can have important roles
during autoimmune diseases, suggesting that the role of
B cells in SLE pathogenesis might be extended beyond
autoantibody production.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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can be efficiently induced by toll-like receptor (TLR) sig-
naling [17-19]. In this context, TLR9 is of great interest
for SLE immunopathology because increased apoptosis
and/or clearance deficiencies in SLE are considered to
result in increased amounts of circulating plasma DNA,
which may act as TLR agonists and subsequently pro-
vide B cell activation signals [20].
Earlier studies showed that SLE B cells responded in a
similar way as healthy donors upon TLR9 stimulation.
However, B cells from patients with severe SLE showed
a reduced secretion of IL-6 and IL-10, and no up-
regulation of activation markers, such as CD86 afterTable 1 Demographic and clinical data, lupus activity (SLEDA
analysis
Patient ID Sex Age, y B cells/μL blood anti-dsDNA IgG, U/m
SLE1 F 61 187 0
SLE2 F 31 320 0
SLE3 F 30 159 0
SLE4 F 25 132 45
SLE5 F 36 216 38
SLE6 F 39 538 50
SLE7 F 22 164 0
SLE8 F 44 108 0
SLE9 F 48 67 75
SLE10 M 20 89 50
SLE11 F 30 305 45
SLE12 F 33 468 0
SLE13 F 23 785 125
SLE14 F 33 110 18
SLE15 F 32 75 60
SLE16 F 37 ND 2,000
SLE17 F 38 192 21
SLE18 F 47 114 1,400
SLE19 F 59 26 0
SLE20 F 30 32 1,000
SLE21 F 51 81 200
SLE22 F 28 56 0
SLE23 F 33 98 0
SLE24 F 32 155 17.5
SLE25 F 29 19 positive
SLE26 M 21 79 positive
SLE27 F 37 118 positive
SLE28 F 74 20 negative
SLE29 F 35 75 positive
SLE30 F 33 35 positive
Patient SLE18 was newly diagnosed and donated blood before immunosuppressive
index; Pred, prednisolone; Aza, azathioprine; MTX, methotrexate; HCQ, hydroxychlorTLR9 engagement compared to healthy donors [21,22].
To reconcile these findings, we undertook a more com-
prehensive study of cytokine production by B cells in
SLE. The current study compared B cells from healthy
donors and SLE patients for production of cytokines and
growth factors, proliferation and expression of activation
markers upon TLR9 stimulation taking the underlying
lupus activity into consideration.
Materials and methods
Patients and controls
For the analysis of cytokine production by B cells,
peripheral blood was collected from 18 SLE patientsI) and individual therapy of the patients at the time of
L SLEDAI Treatment Prednisolone dose, mg/d
7 Pred 5.0
5 Pred, MTX 5.0
4 Pred, MMF 5.0
8 Pred, Aza, HCQ 5.0
8 Pred, Aza 7.5
6 Pred, MMF 5.0
4 Pred 5.0
5 HCQ 0
8 Pred, MMF 5.0
10 Pred, Aza 5.0
6 Pred 5.0
5 Pred 8.0
14 Pred, HCQ 100.0
4 Pred, HCQ 5.0
12 Pred, MMF 8.0
15 Pred, HCQ 25.0
8 Pred, HCQ, MMF 7.5
14 Therapy naive 0
5 Pred, Aza 5.0
5 HCQ 0
6 Pred, Aza 7.5
6 Ciclosporine, Pred 5.0
6 Pred, Aza 5.0
18 Cylophosphamide, Pred 7.5
7 Ciclosporine, Pred -
6 Pred, MMF -
5 Pred, Aza -
5 Antimalarials -
6 Pred, Antimalarials -
7 Pred, MMF -
treatment was started. SLEDAI, systemic lupus erythematosus disease activity
oquine; MMF, mycophenolate mofetil; ND, not detected.
Figure 1 (See legend on next page.)
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Figure 1 Reduced proliferation and activation of toll-like receptor 9 (TLR9)-stimulated B cells from systemic lupus erythematosus (SLE)
patients compared to healthy donors. (A) Representative flow cytometry plots showing the gating strategy and histograms of the frequency
of proliferating B cells and induction of CD38 expression after 2 days of peripheral blood mononuclear cells (PBMC) culture with or without CpG
stimulation. (B) Combined data from 6 SLE patients and 10 healthy donors for the frequency of proliferating (Ki-67+) B cells (left graph) and the
induction of CD38 expression by B cells (right graph). (Mann-Whitney U-test; ns, not significant *P <0.05). HD, healthy donors.
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and 13 healthy donors (12 females/1 male) with a mean
age of 36.7 ± 14.9 years. For the analysis of activation
and IL-10 expression in B cells using flow cytometry
(FC), peripheral blood was collected from 6 female SLE
patients with a mean age of 38.8 ± 12.9 years and 10
healthy donors (8 female/2 male) with a mean age of
32.9 ± 11.1 years. For the analysis of TLR9 expression,
peripheral blood was collected from patients with SLE
(12 female/1 male, 38.4 ± 18.4) and 5 female healthy do-
nors (29.4 ± 5.0).
The study was approved by the local ethics committee
of the Charité Universitätsmedizin Berlin and written
consent was obtained from all donors. The consents are
on file held by the principal investigator and available
for review by the editor-in-chief upon request. All pa-
tients met the revised American College of Rheumatol-
ogy classification criteria for SLE [23]. The disease
activity was assessed using the SLE disease activity index
(SLEDAI) modified according to the SELENA-trial [24].
Details of the clinical characteristics and treatment re-
gimens of the analyzed SLE patients are provided in
Table 1.
Isolation of B cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated with density gradient centrifugation using lympho-
cyte separation medium (PAA Laboratories, Pasching,
Austria) as previously described [25]. Subsequently, B
cells were negatively purified by magnetic activated cell
sorting (MACS®) using the B-cell Isolation Kit II (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions and B cell purity was checked
by flow cytometry. The contamination with CD3+, CD14+
and dead cells was below 5% in all samples.
Lymphocyte staining for flow cytometry
Purified B cells were stained at 4°C for 15 minutes with
antibodies against CD14-PB (M5E2), CD3-PB (UCHT1),
CD27-Cy5 (2E4), CD19-PE-Cy7 (SJ25C1), CD20-PerCP-
Cy5 (L27), and IgD-FITC (IA62) to control the purity
used for the subsequent analyses.
Before and after stimulation, PBMCs were stained first
with antibodies against CD14- Pacific blue (PB) (M5E2),
CD3-PB (UCHT1), CD27-fluorescein isothiocyanate (FITC)
(L128), CD38-PercP-Cy5.5 (HIT2) and CD20-Pacific or-
ange (PO) (H147) for 10 minutes on ice. After washing,PBMCs were incubated with 400 μl of 1 × FACS per-
meabilizing solution 2 (Becton Dickinson (BD) Franklin
Lakes, NJ, USA) for 10 minutes at room temperature (RT).
After permeabilization and washing, PBMCs were stained
with anti-Ki67-PE-Cy7 (B56) and anti-IL-10-APC (JES3-
9D7) and anti-TLR9-PE (eB72-1665) antibodies for 10 mi-
nutes at RT. All antibodies were purchased from BD; beside
Cy5-conjugated anti-CD27 antibody (2E4) (kind gift from
Andreas Thiel, Berlin Center for Regenerative Therapy,
Charité Berlin) and anti-IL-10-APC antibodies purchased
from Miltenyi Biotec. Stained cells were analyzed by FC
using the FACSCanto™II flow-cytometer (BD). FC data were
analyzed using FlowJo (Tree Star, Inc., Ashland, OR, USA).
In vitro stimulation
B cells were stimulated in vitro with CpG 2006 oligo-
nucleotide (CpG) (TIB MolBiol Synthese Labor GmbH,
Berlin, Germany). The cells were resuspended in RPMI
1640 Glutamax supplemented with 10% FCS (Lonza,
Köln, Germany), 5% penicillin/streptomycin, and 0.05 mM
2-mercaptoethanol (Gibco® Life Technologies GmbH,
Darmstadt, Germany). B cells, 105, were seeded and sti-
mulated with 2.5 μg/mL CpG for 48 h at 37°C and
5% CO2. After 2 days of culture, the supernatants were
harvested and frozen at −70°C prior to analysis.
To analyze the IL-10 production by B cells, PBMCs
(106/well) were cultured with CpG 2006 in vitro as de-
scribed [26,27]. Intracellular staining of IL-10 and Ki67
was performed on PBMCs after 2 days of culture. PBMCs
were re-stimulated for 4 h with 10 ng/mL PMA and
1 μM ionomycin including 2 μg/mL brefeldin A for the
last 2 h (all from Sigma Munich, Germany) prior to intra-
cellular staining. Unstimulated cells served as controls.
Cytokine assay
Cryopreserved supernatants were assessed for determin-
ation of cytokine concentration using Bio-Plex® technol-
ogy (Bio-Rad Laboratories, Inc., CA, USA) according to
the manufacturer’s instructions. The cytokines analyzed
were IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/
CXCL8 (chemokine (C-X-C motif ) ligand 8), IL-9, IL-10,
IL-12p70, IL-13, IL-15, IL-17A, eotaxin-1/CCL11 (che-
mokine (C-C motif ) ligand 11), basic fibroblast growth
factors (FGF), granulocyte colony-stimulating factor (G-
CSF), granulocyte macrophage colony-stimulating factor
(GM-CSF), IFN-α2, IFN-γ, IP-10 (IFNγ-induced protein
10)/CXCL10, monocyte chemotactic protein-1 (MCP-1)/
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CCL3, MIP-1β/CCL4, platelet-derived growth factor-BB
(PDGF-BB), regulated on activation, normal T-cell ex-
pressed and secreted (RANTES)/CCL5, vascular endo-
thelial growth factor (VEGF) and TNF-α. The assayFigure 2 Response to toll-like receptor 9 (TLR9) stimulation of B cells
donors. B cells from SLE patients and healthy donors were purified and cu
were collected and cytokine concentrations were measured by bioplex. Gro
TLR9 stimulation of B cells. Group 2 is composed of cytokines with a mode
group 3 reflects cytokines with a very limited increase (<2 fold) after TLR9
granulocyte colony-stimulating factor; G-CSF, granulocyte colony-stimulatin
proteins; PDGF-BB, platelet-derived growth factor-BB; RANTES, regulated on
endothelial growth factor.sensitivity depends on the particular cytokines analyzed
from 0.3 pg/mL for IL-10 to 6.4 pg/mL for IFN-γ. Al-
though all 28 cytokines and growth factors were detec-
table in the supernatant of the B-cell culture; 12 of them
(IL-1β, IL-2, IL-4, IL-5, IL-7, IL-12p70, IL-13, IL-15, GM-from systemic lupus erythematosus (SLE) patients and healthy
ltured with or without CpG. After 2 days of culture, the supernatants
up 1 consists of certain cytokines with strong increase (>4-fold) upon
rate increase (between 2- and 4-fold) upon TLR9 stimulation, while
stimulation (n =18 SLE patients). FGF, fibroblast growth factor; G-CSF,
g factor; IP-10: IFNγ-induced protein 10; MIP, macrophage inflammatory
activation: normal T-cell expressed and secreted; VEGF, vascular
Figure 3 (See legend on next page.)
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Figure 3 Hyporesponsiveness to toll-like receptor 9 (TLR9) stimulation of B cells from systemic lupus erythematosus (SLE) patients in
relation to their disease activity. (A) Heat map of cytokines from group 1 and 2 secreted by B cells upon TLR9 stimulation (dark blue for the
lowest, to red for the highest concentration of cytokine in the supernatant). SLE patients were ordered according to their disease activity from
low systemic lupus erythematosus disease activity index (SLEDAI) in green, to high SLEDAI in red. (B) Direct correlation between individual
cytokines from group 1 and 2 and lupus activity (SLEDAI score). Significant inverse correlation was found between the SLEDAI score and individual
cytokines produced by B cells upon TLR9 stimulation (IL-6, IL-9, IL-17A, IFN-γ, IP-10, MIP-1α, MIP-1β, and TNF-α). Healthy donors (HD) are plotted as
reference. (Spearman r correlation test; *P <0.05 and **P <0.01). IP-10: IFNγ-induced protein 10; MIP, macrophage inflammatory proteins; VEGF, vascular
endothelial growth factor.
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low levels with a mean concentration below 20 pg/mL
after TLR9 stimulation (Additional file 1) and were there-
fore not considered for further analysis.
Statistical analysis
The statistical analysis was performed with SPSS (version
20, IBM, NY, Chicago, IL, USA). To compare data from
healthy donors and SLE patients, the nonparametric Mann-
Whitney U-test was used. The Wilcoxon test was used to
compare results after TLR9 stimulation with unstimulated
controls for the cytokine production. Multiple compari-
sons were performed using one way analysis of variance
(ANOVA) with Dunnett’s post hoc test. To correlate cyto-
kine levels with SLEDAI scores or with dsDNA titers,
Spearman correlation analysis was performed. P-values
<0.05 were considered statistically significant. The statis-
tical tests used are indicated in each figure legend.
Results
In the current study, a comprehensive analysis was per-
formed to assess the capacity of B cells from SLE patients
to respond to TLR9 stimulation in terms of proliferation,
activation, and cytokine production in relation with cli-
nical lupus activity using SLEDAI.
B cells from SLE patients have a reduced proliferation and
activation upon TLR9 stimulation
We first evaluated the response of B cells to TLR9 stimu-
lation in terms of proliferation and activation. The fre-
quency of proliferating cells (% of Ki67+ B cells), and the
upregulation of the activation marker CD38 after 2-day
culture with CpG were analyzed by FC (Figure 1A). CpG
induced B cell proliferation independently of B cell recep-
tor (BCR) engagement; however, SLE patients had a lower
frequency of proliferating B cells upon TLR9 stimulation
in comparison with healthy donors (P <0.05) (Figure 1B,
left graph). Moreover, activation of B cells was evaluated
by upregulation of CD38 expression (mean fluorescence
intensity, MFI) upon TLR9 stimulation. B cells from
healthy donors significantly upregulated CD38, resulting
in a 3-fold increase after TLR9 stimulation, while theresponse of B cells from SLE patients was significantly
lower (Figure 1B, right graph, P <0.05).
B cells from SLE patients secrete fewer cytokines in
relation to the disease activity
Subsequently, the influence of TLR9 stimulation on
cytokine production was evaluated by analyzing the
concentrations of 28 cytokines and growth factors in the
supernatants of B cell cultures from healthy donors and
SLE patients using BioPlex technology. The cytokines
were grouped according to the level of their induction
upon TLR9 engagement compared to unstimulated B
cells. The first group included cytokines showing more
than a 4-fold increase after TLR9 stimulation and com-
prised IL-1ra, TNF-α, IL-6, and IL-10, the chemokines
IP-10, MIP-1α, -1β, and the growth factor VEGF. The
second group was defined by a moderate (2- to 4-fold)
increase after TLR9 stimulation, and comprised IL-8,
IL-9, IL-17A and IFN-γ. A third group of growth factors
and chemokines, defined by a very small increase or no
increase after TLR9 stimulation (maximum 2-fold in-
crease) comprised basic FGF, G-CSF, PDGF-BB, and
RANTES (Figure 2). Overall, the profiles of cytokine se-
cretion observed in the supernatants of cultured B cells
from SLE patients and healthy donors shared very large
similarities. We found that none of the cytokines from
groups 1 and 2 were secreted at a higher level by B cells
from SLE patients, but rather at lower levels in compari-
son to B cells from healthy donors. Since earlier reports
found that B cells from active SLE patients were less re-
sponsive to TLR9 stimulation in terms of IL-6 and IL-10
production [21], we analyzed the relation between the
cytokines from groups 1 and 2 and the disease activity
(SLEDAI) by using a heat map (Figure 3A). When the
patients were ordered according to their SLEDAI, it be-
came apparent that B cells from patients with SLEDAI
of 4 (n = 3) produced larger amounts of cytokines than
those from patients presenting with a SLEDAI higher
than 14 (n = 3). The remaining patients with a SLEDAI
between 4 and 14 displayed an intermediate but clearly
ranked profile (Figure 3A). In greater detail, correlation
analyses of individual cytokines revealed significant in-
verse correlations between the SLEDAI and inducible
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MIP-1β, TNF-α, and VEGF of TLR9-activated SLE B
cells (Figure 3B). In contrast, there was no correlationFigure 4 Reduced IL-6, vascular endothelial growth factor (VEGF), and
stimulation in active systemic lupus erythematosus (SLE) patients com
cytokines (group 1 and 2) upon TLR9 stimulation by healthy donors with S
disease activity (SLEDAI <6, n = 6) and high disease activity (SLEDAI ≥6, n =
were significantly reduced in SLE with high SLEDAI compared to healthy d
*P <0.05). (B) Representative flow cytometry analysis plots showing IL-10-p
(PBMC) culture without (left) or with (right) CpG stimulation. Combined da
IL-10-producing B cells (left graph) and the overall production of IL-10 by B
amount per cell) (Mann-Whitney U-test and Wilcoxon test; ns: not significanbetween the spontaneous (unstimulated) production of
these cytokines and the SLEDAI, highlighting the specifi-
city of this association with TLR9 signaling.IL-1ra production by B cells upon toll-like receptor 9 (TLR9)
pared to healthy donors (HD). (A) To compare the production of
LE patients, the SLE cohort was divided in two groups with low
12). IL-6, VEGF, and IL-1ra produced by B cells upon TLR9 stimulation
onors (one way analysis of variance with Dunnett’s post hoc test,
roducing B cells after 2 days of peripheral blood mononuclear cells
ta from 6 SLE patients and 10 healthy controls for the frequency of
cells (right graph, MFI = mean fluorescence intensity, reflecting
t, *P <0.05, **P <0.01).
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cells from patients with active SLE produced fewer cyto-
kines than those from patients with less active disease. In
order to further compare the data to healthy donors, we
divided the patients into two groups with high (≥6) and
low SLEDAI (<6) [28] (Figure 4A). Notably, the produc-
tion of IL-6, IL-1ra, and VEGF by B cells was significantly
reduced in patients with active SLE with a SLEDAI ≥6
compared to healthy donors. The secretion of IL-10 was
also reduced by trend, although not statistically significant
(P = 0.051). FC analysis of IL-10-producing B cells showed
a significantly increased frequency of IL-10+ B cells after
TLR9 stimulation (Figure 4B). However, there was no
difference between B cells from SLE patients and healthy
donors. While the generation of IL-10-producing B cells
was not reduced in culture of B cells from SLE patients,Figure 5 Reduced cytokine production by B cells after toll-like receptor
titers. The anti-dsDNA antibodies were measured in the serum of the patie
number of significant inverse correlations between serum anti-dsDNA-antib
MIP-1α, MIP-1β, TNF-α, and VEGF) in SLE patients (Spearman r correlation te
VEGF, vascular endothelial growth factor.there was a clear reduction of the amount of IL-10 in-
duced in individual IL-10+ B cells compared to healthy do-
nors as shown by the MFI of intracellular IL-10
(Figure 4B).
Inverse correlation between cytokine production and
anti-dsDNA autoantibodies
A key serologic parameter reflecting the breakdown of tol-
erance and related with lupus disease activity are anti-
dsDNA autoantibodies that have been linked to TLR9
stimulation [29]. We found a significant (P <0.05) inverse
correlation between the serum anti-dsDNA titers and
amounts of IL-1ra, IL-6, IL-9, IL-17A, IFN-γ, MIP-1α, -1β,
TNF-α, and VEGF produced by TLR9-activated B cells
from SLE patients (Figure 5). Thus, the higher anti-
dsDNA antibody titer in serum, the lower was the level9 (TLR9) stimulation in patients with higher anti-dsDNA antibody
nts simultaneously with the TLR9 activation of B cells. There were a
ody titers and TLR9 induced cytokines (IL-1ra, IL-6, IL-9, IL-17A, IFN-γ,
st, P <0.05 and **P <0.01). MIP, macrophage inflammatory proteins;
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B cells.
TLR9 is downregulated in patients with active SLE
In an attempt to explain the reduced response of B cells
from SLE patients to TLR9 agonist compared to controls,
we analyzed whether TLR9 was differentially expressed by
these cells. FC analysis of TLR9 expression in B cells from
healthy donors and SLE patients showed that the MFI of
TLR9 was similar in B cells from healthy donors compared
to those from SLE patients (242.8 ± 41.9 and 218.5 ± 53.2)
(Figure 6). However, a significant reduction of TLR9 ex-
pression was found for B cells from SLE patients with a
SLEDAI ≥6 (191.8 ± 19.5) (Figure 6). This result is in line
with our observations on cytokine production, suggesting
that the observed reduction in CpG responsiveness for B
cells from patients with high disease activity could be re-
lated to a down-modulation of TLR9 expression.
Discussion
Our results confirm that B cells from SLE patients globally
show the same pattern of cytokine expression compared to
B cells from healthy donors upon TLR9 stimulation [30].
However, our study also provides evidence that B cells
from patients with severe SLE are hyporesponsive to TLR9
stimulation in terms of activation, proliferation, and cyto-
kine production compared with B cells from healthy do-
nors. Moreover, the reduction of cytokine production upon
TLR9 stimulation was correlated with lupus activity andFigure 6 Reduced expression of toll-like receptor 9 (TLR9) by B cells f
Representative flow cytometry histogram showing TLR9 staining for B cells
SLE patients and 4 healthy donors (HD), respectively, did not show a signif
active SLE (SLE disease activity index (SLEDAI) ≥6) were found to express re
panel). Hhistogram: red line TLR9, gray line isotype- phycoerythrin (PE) andanti-ds-DNA antibody titers. Patients with high SLEDAI
score (SLEDAI ≥6) showed a lower secretion of IL-6,
IL-1ra, IL-10, and VEGF upon TLR9 stimulation in com-
parison to healthy donors as well as a lower expression of
TLR9. Of note, a previous report documented that SLE
B cells expressed significantly more TLR9 than B cells from
healthy donors [31], especially in patients with increased
anti-dsDNA antibody titers and high disease activity
[32,33]. Although the reason for the discrepancy between
our results and this study remains unexplained, it seems
coherent that B cells from patients with active SLE have
both reduced TLR9 expression and a lower response to
TLR9 agonist than B cells from healthy donors. Remar-
kably, we did not identify any cytokine that was induced to
a larger extent in B cells from SLE patients compared to
healthy donors.
In this study the mechanism responsible for lower ex-
pression of TLR9 by B cells from patients with active SLE
remains to be delineated. A possibility is that B cells from
patients with severe SLE are hyporesponsive to TLR9
stimulation because of an overstimulation in vivo by circu-
lating DNA in the serum of the patients [21]. This might
indicate an exhausted or post-activation state as already
described for T cells from SLE patients [1], or a state of
tolerance to TLR-stimulation as described for myeloid
cells [34]. Another reason might be that TLR9 signaling
limits the life span of anti-DNA B cells, leading to an eli-
mination of the B cells expressing high amounts of TLR9,
as shown in an SLE mouse model [35]. In any case, such arom active systemic lupus erythematosus (SLE) patients.
(left). Combined data for TLR9 detection of B cells obtained from 6
icant difference in TLR9 detection, but B cells from patients with more
duced TLR9 (Mann-Whitney U-test; ns: not significant; *P <0.05) (right
black line control antibody; MFI: mean fluorescence intensity of TLR9.
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the immune system to reduce the availability of this poten-
tially deleterious pathway as the disease worsens. Alter-
natively, intrinsic TLR9 signaling in B cells might be
beneficial in SLE so that the observed impairment could
play a role in exacerbation of the disease. It is currently
difficult to evaluate whether intrinsic TLR9 signaling in B
cells is beneficial or deleterious during chronic SLE. TLR9-
stimulated B cells secreted inflammatory cytokines, such
as IL-6, TNF-α, MIP-1α, -1β, and IP-10, but also anti-
inflammatory cytokines such as IL-1ra [36], and IL-10
[13,37]. We found reduced IL-10 production by B cells
upon TLR9 stimulation for active SLE patients, consistent
with previous reports [21]. IL-1ra and VEGF have also
been described to have immunosuppressive effects, and
were also produced in lower amounts by B cells from ac-
tive patients compared to healthy donors. Indeed, IL-1ra is
a receptor antagonist that inhibits the IL-1 pathway and
provides an important anti-inflammatory mechanism [38].
VEGF has also been described as an immunosuppressive
cytokine that inhibits the functional maturation of den-
dritic cells and T-cell development [39,40]. The link
between SLE pathogenesis and the reduced expression of
IL-1ra and VEGF by B cells remains to be further
analyzed.
The capacity of B cells to produce cytokines can be influ-
enced by a number of variables in addition to the disease
activity, including immune therapies. In this regard, the
current data do not indicate that certain therapies (Table 1)
may have major effects on cytokine-production by B cells
upon stimulation in vitro. In particular there was no
significant difference in the amount of cytokines produced
by B cells from patients treated with hydroxychloroquine
(n = 6) or not (n = 12) (data not shown), although this
drug is considered to inhibit TLR9-signaling [41]. We also
correlated the dosage of prednisolone (mg/day) taken by
the patient at the moment of the study and the cytokine
level produced by B cells upon TLR9 stimulation (data not
shown). Only the concentration of IL-9, IL-17A, IFN-γ and
RANTES showed a significant inverse correlation with the
dosage of prednisolone used by the patients. Nevertheless,
only two patients received more than 10 mg prednisolone/
day in this study. In addition, one newly diagnosed and
untreated patient (SLE18) with a SLEDAI of 14 showed a
very low cytokine production, in a range comparable to the
other patients with active SLE who were under immu-
nosuppressive treatment. Thus, the described low cytokine
production upon TLR9 stimulation by B cells of active
patients seems related to SLE disease activity per se rather
than to immunosuppressive interventions.
Conclusion
The cytokine production by B cells from patients with se-
vere SLE upon TLR9-engagement ex vivo is substantiallylower than in healthy donors. The current data are
consistent with an exhaustion of B cells, or an induction
of TLR-tolerance post-activation (by diminished TLR9
expression) depending on lupus disease activity. Under-
standing the molecular mechanism of reduced cytokine
production by B cells upon TLR9 engagement in SLE
might provide new insights into the pathogenesis of SLE.
Additional file
Additional file 1: Figure S1. Cytokines lacking substantial production
upon toll-like receptor 9 (TLR9) stimulation by B cells from healthy donors
(white) and patients suffering from systemic lupus erythematosus (SLE)
(gray). B cells from SLE-patients and healthy donors were purified and
cultured with or without CpG, the cytokine concentrations were measured
in supernatants collected after 2 days of culture by bioplex. The cytokines
shown were detectable at very low levels after B-cell stimulation by TLR
ligation using CpG (<20 pg/mL of supernatant).
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